Skip to main content
Caplight Logo









Contraline

Contraline

Private
Charlottesville, VirginiaHealthcare & Life Scienceshttps://www.contraline.com/

Last Round

Series B

Jun 2, 2026

Est. Valuation

$53.5M

Total Funding Raised

$114.22M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Contraline is a biotechnology company developing a long-lasting, non-hormonal, and reversible male contraceptive hydrogel.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B2C

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

male contraceptivemale birth controlhydrogel implantvas deferensnon-hormonal contraceptionreversible vasectomyreproductive healthmedical deviceurologybiotechnologyvasalgel

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Contraline Comparables

Compare Contraline with similar companies based on industry and business-model similarity.

Contraline comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Next Life Sciences
91%
VasDeBlock medical ApS
79%
Population Council
72%

Contraline Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 2, 2026
Series A ExtensionNov 10, 2022
Series AOct 20, 2021
GrantNov 18, 2020
GrantJan 24, 2019
Seed
Apr 18, 2017

Key People

Founding team and executive leadership

Kevin Eisenfrats

Co-Founder and CEO

Founding Team

Yelena Tropsha

Chief Technology Officer

Executive Team

James P. Tursi

Chief Scientific Officer

Executive Team

Contraline Investors

Notable investors and investment history

Contraline investors
InvestorRounds
Male Contraceptive InitiativeGrant
RA Capital ManagementSeries B
GVSeries B, Series A Extension
Metaplanet HoldingsSeries A, Series A Extension
Founders FundSeries A, Seed
Invus OpportunitiesSeries B
Virginia Innovation Partnership CorporationSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 17, 2026

    Grew 15% QoQ, from 26 to 30 employees.

  • Jun 22, 2026

    Grew 25% QoQ, from 24 to 30 employees.

Contraline Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Contraline Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Contraline's valuation, stock price, and market status.

Firmographic Details

HeadquartersCharlottesville, Virginia
Employee Range30
Year Founded2015
Last FundingJun 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?